Coherus Oncology (CHRS) Cash from Investing Activities (2013 - 2026)

Coherus Oncology has disclosed Cash from Investing Activities across 14 years of filings, most recently posting $30.7 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $30.7 million, up 275.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $423.2 million (up 4102.03% YoY), and the FY2025 annual result was $375.1 million, up 62.85% from the prior year.
• Cash from Investing Activities came in at $30.7 million for Q1 2026 at Coherus Oncology, up from -$2.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $462.6 million in Q2 2025 to a low of -$129.9 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is $444000.0 (2024), against an average of $36.1 million.
• Across the five-year window, Cash from Investing Activities surged 11160.39% in 2023 and tumbled 15241.22% in 2025, its largest moves.
• Coherus Oncology's Cash from Investing Activities stood at -$129.9 million in 2022, then surged by 127.1% to $35.2 million in 2023, then sank by 101.54% to -$542000.0 in 2024, then sank by 423.62% to -$2.8 million in 2025, then soared by 1180.16% to $30.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $30.7 million (Q1 2026), -$2.8 million (Q4 2025), and -$67.2 million (Q3 2025), per Business Quant data.